Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search

Author index

Page Path
HOME > BROWSE ARTICLES > Author index
Search
Yu Mi Kang  (Kang YM) 3 Articles
Effects of Incretin-Based Therapies on Diabetic Microvascular Complications
Yu Mi Kang, Chang Hee Jung
Endocrinol Metab. 2017;32(3):316-325.   Published online September 18, 2017
DOI: https://doi.org/10.3803/EnM.2017.32.3.316
  • 4,886 View
  • 57 Download
  • 10 Web of Science
  • 11 Crossref
AbstractAbstract PDFPubReader   

The morbidity and mortality associated with diabetic complications impose a huge socioeconomic burden worldwide. Therefore, the ultimate goal of managing diabetes mellitus (DM) is to lower the risk of macrovascular complications and highly morbid microvascular complications such as diabetic nephropathy (DN) and diabetic retinopathy (DR). Potential benefits of incretin-based therapies such as glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors on the diabetic macrovascular complications have been recently suggested, owing to their pleiotropic effects on multiple organ systems. However, studies primarily investigating the role of these therapies in diabetic microvascular complications are rare. Nevertheless, preclinical and limited clinical data suggest the potential protective effect of incretin-based agents against DN and DR via their anti-inflammatory, antioxidative, and antiapoptotic properties. Evidence also suggests that these incretin-dependent and independent beneficial effects are not necessarily associated with the glucose-lowering properties of GLP-1 RAs and DPP-4 inhibitors. Hence, in this review, we revisit the preclinical and clinical evidence of incretin-based therapy for DR and DN, the two most common, morbid complications in individuals with DM. In addition, the review discusses a few recent studies raising concerns of aggravating DR with the use of incretin-based therapies.

Citations

Citations to this article as recorded by  
  • Efficacy and Safety of the Utilization of Dipeptidyl Peptidase IV Inhibitors in Diabetic Patients with Chronic Kidney Disease: A Meta-Analysis of Randomized Clinical Trials
    Moeber Mahzari, Muhannad Alqirnas, Moustafa Alhamadh, Faisal Alrasheed, Abdulrahman Alhabeeb, Wedad Al Madani, Hussain Aldera
    Diabetes, Metabolic Syndrome and Obesity.2024; Volume 17: 1425.     CrossRef
  • Comparative Effectiveness of GLP-1 Receptor Agonists, SGLT2 Inhibitors, DPP-4 Inhibitors, and Sulfonylureas for Sight-Threatening Diabetic Retinopathy
    Andrew J. Barkmeier, Jeph Herrin, Kavya Sindhu Swarna, Yihong Deng, Eric C. Polley, Guillermo E. Umpierrez, Rodolfo J. Galindo, Joseph S. Ross, Mindy M. Mickelson, Rozalina G. McCoy
    Ophthalmology Retina.2024;[Epub]     CrossRef
  • Anti-Inflammatory Effects of GLP-1R Activation in the Retina
    Alessandra Puddu, Davide Maggi
    International Journal of Molecular Sciences.2022; 23(20): 12428.     CrossRef
  • Diabetes and Its Complications: Therapies Available, Anticipated and Aspired
    Anu Grover, Komal Sharma, Suresh Gautam, Srishti Gautam, Monica Gulati, Sachin Kumar Singh
    Current Diabetes Reviews.2021; 17(4): 397.     CrossRef
  • SGLT2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors in Diabetes and Microvascular Complications: A Review
    Christopher El Mouhayyar, Ruba Riachy, Abir Bou Khalil, Asaad Eid, Sami Azar
    International Journal of Endocrinology.2020; 2020: 1.     CrossRef
  • Novel therapeutic agents for the treatment of diabetic kidney disease
    Rachel E. Hartman, P.S.S. Rao, Mariann D. Churchwell, Susan J. Lewis
    Expert Opinion on Investigational Drugs.2020; 29(11): 1277.     CrossRef
  • Nationwide Trends in Pancreatitis and Pancreatic Cancer Risk Among Patients With Newly Diagnosed Type 2 Diabetes Receiving Dipeptidyl Peptidase 4 Inhibitors
    Minyoung Lee, Jiyu Sun, Minkyung Han, Yongin Cho, Ji-Yeon Lee, Chung Mo Nam, Eun Seok Kang
    Diabetes Care.2019; 42(11): 2057.     CrossRef
  • Effects of Dipeptidyl Peptidase-4 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis
    Jae Hyun Bae, Sunhee Kim, Eun-Gee Park, Sin Gon Kim, Seokyung Hahn, Nam Hoon Kim
    Endocrinology and Metabolism.2019; 34(1): 80.     CrossRef
  • Serum adipocytokines are associated with microalbuminuria in patients with type 1 diabetes and incipient chronic complications
    Tomislav Bulum, Marijana Vučić Lovrenčić, Martina Tomić, Sandra Vučković-Rebrina, Vinko Roso, Branko Kolarić, Vladimir Vuksan, Lea Duvnjak
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2019; 13(1): 496.     CrossRef
  • Protective Effects of Incretin Against Age-Related Diseases
    Di Zhang, Mingzhu Ma, Yueze Liu
    Current Drug Delivery.2019; 16(9): 793.     CrossRef
  • The role of dipeptidylpeptidase-4 inhibitors in management of cardiovascular disease in diabetes; focus on linagliptin
    Annayya R. Aroor, Camila Manrique-Acevedo, Vincent G. DeMarco
    Cardiovascular Diabetology.2018;[Epub]     CrossRef
Close layer
Obesity and Metabolism
Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists
Yu Mi Kang, Chang Hee Jung
Endocrinol Metab. 2016;31(2):258-274.   Published online April 25, 2016
DOI: https://doi.org/10.3803/EnM.2016.31.2.258
  • 6,816 View
  • 93 Download
  • 31 Web of Science
  • 33 Crossref
AbstractAbstract PDFPubReader   

Glucagon-like peptide-1 (GLP-1) is a member of the proglucagon incretin family, and GLP-1 receptor agonists (RAs) have been introduced as a new class of antidiabetic medications in the past decade. The benefits of GLP-1 RAs are derived from their pleiotropic effects, which include glucose-dependent insulin secretion, suppressed glucagon secretion, and reduced appetite. Moreover, GLP-1 RAs also exert beneficial roles on multiple organ systems in which the GLP-1 receptors exist, including the cardiovascular system. Cardiovascular effects of GLP-1 RAs have been of great interest since the burden from cardiovascular diseases (CVD) has been unbearably increasing in a diabetic population worldwide, despite strict glycemic control and advanced therapeutic techniques to treat CVD. Preclinical studies have already demonstrated the beneficial effects of GLP-1 on myocardium and vascular endothelium, and many clinical studies evaluating changes in surrogate markers of CVD have suggested potential benefits from the use of GLP-1 RAs. Data from numerous clinical trials primarily evaluating the antihyperglycemic effects of multiple GLP-1 RAs have also revealed that changes in most CVD risk markers reported as secondary outcomes have been in favor of GLP-1 RAs treatment. However, to date, there is only one randomized clinical trial of GLP-1 RAs (the ELIXA study) evaluating major cardiovascular events as their primary outcomes, and in this study, a neutral cardiovascular effect of lixisenatide was observed in high-risk diabetic subjects. Therefore, the results of ongoing CVD outcome trials with the use of GLP-1 RAs should be awaited to elucidate the translation of benefits previously seen in CVD risk marker studies into large clinical trials with primary cardiovascular outcomes.

Citations

Citations to this article as recorded by  
  • Cardioprotective Actions of a Glucagon‐like Peptide‐1 Receptor Agonist on Hearts Donated After Circulatory Death
    Sachiko Kadowaki, M. Ahsan Siraj, Weiden Chen, Jian Wang, Marlee Parker, Anita Nagy, Chun‐Po Steve Fan, Kyle Runeckles, Jing Li, Junko Kobayashi, Christoph Haller, Mansoor Husain, Osami Honjo
    Journal of the American Heart Association.2023;[Epub]     CrossRef
  • The role of dipeptidyl peptidase-IV in abdominal aortic aneurysm pathogenesis: A systematic review
    Elisha Ngetich, Pierfrancesco Lapolla, Anirudh Chandrashekar, Ashok Handa, Regent Lee
    Vascular Medicine.2022; 27(1): 77.     CrossRef
  • Glucagon-like Peptide-1 Receptor Agonists in the Management of Type 2 Diabetes Mellitus and Obesity: The Impact of Pharmacological Properties and Genetic Factors
    Jasna Klen, Vita Dolžan
    International Journal of Molecular Sciences.2022; 23(7): 3451.     CrossRef
  • Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials
    Jing Qin, Li Song
    BMC Endocrine Disorders.2022;[Epub]     CrossRef
  • Role of G-protein coupled receptor (GPCRs)/(GPR-120) as an agonists in diabetic wound healing
    Jagat Pal Yadav, Dinesh Kumar Patel, Prateek Pathak, Maria Grishina
    Obesity Medicine.2022; 36: 100466.     CrossRef
  • Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms
    Bruno Vergès, Victor Aboyans, Denis Angoulvant, Pierre Boutouyrie, Bertrand Cariou, Fabien Hyafil, Kamel Mohammedi, Pierre Amarenco
    Cardiovascular Diabetology.2022;[Epub]     CrossRef
  • Changing Fields-Diabetes Medications Invading the Cardiovascular Space
    Lauren D. Breite, Mackenzie Steck, Brandon Tate Cutshall, Samarth P. Shah, Brandon E. Cave
    Current Problems in Cardiology.2021; 46(3): 100736.     CrossRef
  • PEGDA/HA mineralized hydrogel loaded with Exendin4 promotes bone regeneration in rat models with bone defects by inducing osteogenesis
    Wei Liu, Xiaowei Jing, Zhiwen Xu, Chong Teng
    Journal of Biomaterials Applications.2021; 35(10): 1337.     CrossRef
  • Metabolite G-Protein Coupled Receptors in Cardio-Metabolic Diseases
    Derek Strassheim, Timothy Sullivan, David C. Irwin, Evgenia Gerasimovskaya, Tim Lahm, Dwight J. Klemm, Edward C. Dempsey, Kurt R. Stenmark, Vijaya Karoor
    Cells.2021; 10(12): 3347.     CrossRef
  • PPG neurons in the nucleus of the solitary tract modulate heart rate but do not mediate GLP-1 receptor agonist-induced tachycardia in mice
    Marie K. Holt, Daniel R. Cook, Daniel I. Brierley, James E. Richards, Frank Reimann, Alexander V. Gourine, Nephtali Marina, Stefan Trapp
    Molecular Metabolism.2020; 39: 101024.     CrossRef
  • A glycosylated Fc‐fused glucagon‐like peptide‐1 receptor agonist exhibits equivalent glucose lowering to but fewer gastrointestinal side effects than dulaglutide
    In Bok An, Mi Sun Byun, Sang In Yang, Yuri Choi, Jung Won Woo, Hak Chul Jang, Young Chul Sung
    Diabetes, Obesity and Metabolism.2020; 22(8): 1455.     CrossRef
  • Glucagon-Like Peptide-1 Receptor Agonists in Adult Patients With Type 2 Diabetes: Review of Cardiovascular Outcome Trials
    Elodie M. Varin, Brent A. McLean, Julie A. Lovshin
    Canadian Journal of Diabetes.2020; 44(1): 68.     CrossRef
  • Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors
    Alexandros Sachinidis, Dragana Nikolic, Anca Pantea Stoian, Nikolaos Papanas, Omer Tarar, Ali A. Rizvi, Manfredi Rizzo
    Metabolism.2020; 111: 154343.     CrossRef
  • GLP-1 receptor agonist liraglutide protects cardiomyocytes from IL-1β-induced metabolic disturbance and mitochondrial dysfunction
    Lili Zhang, Jiali Tian, Sujuan Diao, Guowei Zhang, Mochao Xiao, Dong Chang
    Chemico-Biological Interactions.2020; 332: 109252.     CrossRef
  • Predictors of Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes and Obesity
    Alina Yu. Babenko, Daria A. Savitskaya, Yulia A. Kononova, Aleksandra Yu. Trofimova, Anna V. Simanenkova, Elena Yu. Vasilyeva, Evgeny V. Shlyakhto
    Journal of Diabetes Research.2019; 2019: 1.     CrossRef
  • Predictors of effectiveness of glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes and obesity
    Ekaterina V. Tikhonenko, Alina Y. Babenko, Evgeny V. Shlyakhto
    Obesity and metabolism.2019; 15(4): 22.     CrossRef
  • Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials
    Yu Mi Kang, Yun Kyung Cho, Jiwoo Lee, Seung Eun Lee, Woo Je Lee, Joong-Yeol Park, Ye-Jee Kim, Chang Hee Jung, Michael A. Nauck
    Diabetes & Metabolism Journal.2019; 43(4): 410.     CrossRef
  • Diabetes, Incretin Therapy and Thoracic Aortic Aneurysm – What Does the Evidence Show?
    Camilla Krizhanovskii , Anders Franco-Cereceda
    Current Vascular Pharmacology.2019; 17(5): 432.     CrossRef
  • Cardiovascular Effects of Different GLP-1 Receptor Agonists in Patients with Type 2 Diabetes
    Gül Bahtiyar, Jean Pujals-Kury, Alan Sacerdote
    Current Diabetes Reports.2018;[Epub]     CrossRef
  • Efficacy From Strange Sources
    Lawrence J. Lesko
    Clinical Pharmacology & Therapeutics.2018; 103(2): 253.     CrossRef
  • Exogenous SERP1 attenuates restenosis by restoring GLP-1 receptor activity in diabetic rats following vascular injury
    Lishuai Feng, Jianbo Wang, Xu Ma
    Biomedicine & Pharmacotherapy.2018; 103: 290.     CrossRef
  • Exenatide exhibits anti‐inflammatory properties and modulates endothelial response to tumor necrosis factor α‐mediated activation
    Wojciech Garczorz, Enrique Gallego‐Colon, Agnieszka Kosowska, Agnieszka Kłych‐Ratuszny, Michał Woźniak, Wiesław Marcol, K.J. Niesner, Tomasz Francuz
    Cardiovascular Therapeutics.2018;[Epub]     CrossRef
  • Molecular and clinical roles of incretin-based drugs in patients with heart failure
    Bassant Orabi, Rasha Kaddoura, Amr S. Omar, Cornelia Carr, Abdulaziz Alkhulaifi
    Heart Failure Reviews.2018; 23(3): 363.     CrossRef
  • The effects of Exendin-4 on bone marrow-derived mesenchymal cells
    Paola Luciani, Benedetta Fibbi, Benedetta Mazzanti, Cristiana Deledda, Lara Ballerini, Alessandra Aldinucci, Susanna Benvenuti, Riccardo Saccardi, Alessandro Peri
    Endocrine.2018; 60(3): 423.     CrossRef
  • Real-world clinical experience of Xultophy in the management of patients with type 2 diabetes in a secondary care clinic
    David M. Williams, Natasha Shrikrishnapalasuriyar, Waheeba Syed, Win L. Yin, Richard Chudleigh, Stephen C. Bain, David E. Price, Jeffrey W. Stephens
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2018; 12(6): 1079.     CrossRef
  • Pharmacological Applications of Bile Acids and Their Derivatives in the Treatment of Metabolic Syndrome
    Maja Ðanić, Bojan Stanimirov, Nebojša Pavlović, Svetlana Goločorbin-Kon, Hani Al-Salami, Karmen Stankov, Momir Mikov
    Frontiers in Pharmacology.2018;[Epub]     CrossRef
  • Cardiovascular Outcome Trials of Diabetes and Obesity Drugs: Implications for Conditional Approval and Early Phase Clinical Development
    Andrew J. Krentz, Gerardo Rodriguez-Araujo
    Pharmaceutical Medicine.2017; 31(6): 399.     CrossRef
  • Articles inEndocrinology and Metabolismin 2016
    Won-Young Lee
    Endocrinology and Metabolism.2017; 32(1): 62.     CrossRef
  • GLP-1R as a Target for the Treatment of Diabetic Retinopathy: Friend or Foe?
    Rafael Simó, Cristina Hernández
    Diabetes.2017; 66(6): 1453.     CrossRef
  • GLP-1 receptor agonists and heart failure in diabetes
    André J. Scheen
    Diabetes & Metabolism.2017; 43: 2S13.     CrossRef
  • Effects of Incretin-Based Therapies on Diabetic Microvascular Complications
    Yu Mi Kang, Chang Hee Jung
    Endocrinology and Metabolism.2017; 32(3): 316.     CrossRef
  • Historique des études cardiovasculaires : de l’UGDP… aux dernières études
    A.-J. Scheen
    Médecine des Maladies Métaboliques.2017; 11: 2S15.     CrossRef
  • Cardiovascular safety and benefits of GLP-1 receptor agonists
    Niels B. Dalsgaard, Andreas Brønden, Tina Vilsbøll, Filip K. Knop
    Expert Opinion on Drug Safety.2017; 16(3): 351.     CrossRef
Close layer
Adrenal gland
Multiple Myeloma in a Patient with Acromegaly
Yu Mi Kang, Jong Han Choi, Min Jung Lee, Ari Ahn, Chan-Jeoung Park, Kiju Chang, Seyoung Seo, Sun In Hong, Min-Seon Kim
Endocrinol Metab. 2015;30(1):110-115.   Published online March 27, 2015
DOI: https://doi.org/10.3803/EnM.2015.30.1.110
  • 5,243 View
  • 36 Download
  • 2 Web of Science
  • 1 Crossref
AbstractAbstract PDFPubReader   

Acromegaly is a slowly progressing condition resulting from excess growth hormone (GH), generally caused by a GH-secreting pituitary adenoma. Cancer is the third most common cause of mortality in patients with acromegaly, and insulin-like growth factor 1 (IGF-1) is known to influence tumor formation by increasing cell proliferation and inhibiting apoptosis. Multiple myeloma (MM) is a plasma cell neoplasm, and previous studies have suggested the possible role of IGF-1 in its development of MM. However, no cases of acromegaly accompanied with MM have been reported in Asia to date. We here report the case of a 58-year-old woman with acromegaly accompanied with MM who presented with longstanding acromegalic manifestations resulting from a GH-secreting pituitary adenoma and also exhibited anemia, a reversed albumin/globulin ratio, and plasmacytosis on bone marrow examination. Because IGF-1 has been suggested to play an important role in the development and progression of MM, the patient promptly underwent surgical removal of the pituitary adenoma via a transsphenoidal approach. Since there is currently no consensus on therapeutic guidelines and suggested prognosis for MM with acromegaly, long-term follow-up of such cases is needed.

Citations

Citations to this article as recorded by  
  • Co-Occurrence of Acromegaly and Hematological Disorders: A Myth or Common Pathogenic Mechanism
    Prakamya Gupta, Pinaki Dutta
    Integrative Medicine International.2017; 4(1-2): 94.     CrossRef
Close layer

Endocrinol Metab : Endocrinology and Metabolism